A diary of what
actually works.
Independent, evidence-led reviews of GLP-1s, peptides, infusions and aesthetic procedures, written for women who want the study notes before the sponsored post.
“The oral GLP-1 watchlist: what pill convenience does and does not solve.”
in glow.
Orforglipron and the oral GLP-1 watchlist.
Why a daily pill could change the GLP-1 market — and why convenience still does not answer efficacy, safety, access, and maintenance questions.
Amycretin, CagriSema, and the amylin moment.
The next metabolic medicine story may be less about one receptor and more about multi-pathway satiety signals.
The maintenance plan after GLP-1 weight loss.
Plateaus, protein, resistance training, coverage loss, dose changes, and the question everyone postpones: what happens if you stop?
Treatment Intelligence Hub
Guides · tools · medical sources
GLP-1 Guide
Start with the plain-English overview of semaglutide, tirzepatide, access, safety, and maintenance.
Comparison Suite
Use five interactive education-only tools for therapy comparison, cost, safety, nutrition, and timelines.
Doctor Questions
Bring a structured checklist to the clinician conversation instead of a TikTok protocol.
Compounded GLP-1s
Understand FDA concerns, sourcing questions, and why approved-product data cannot be copy-pasted.
Peptide Evidence Guide
Separate approved medicines and investigational science from wellness-market peptide claims.
Pipeline Watchlist
Track retatrutide, CagriSema, amycretin, oral GLP-1s, and metabolic-liver crossover therapies without access hype.
Oral GLP-1s
Understand orforglipron, oral semaglutide, pill convenience, and evidence gaps.
Maintenance Plan
Plan for plateaus, protein, strength, dose changes, coverage shifts, and stopping conversations.
Medical Sources
Review the FDA, NIH, MedlinePlus, PubMed, and trial links behind the site’s claims.
Content Plan
See the editorial roadmap, SEO queue, and validation checklist for the next buildout.
The Cover Review
May 2026 · 12 min read
Retatrutide and “anti-aging” peptides: what the evidence can actually support.
A source-backed review of a viral retatrutide, GHK-Cu, and MOTS-c video: where the biology is plausible, where human data exists, and where the claims outrun the evidence.
The Index
12 reviews · Updated weekly
Orforglipron and the oral GLP-1 watchlist.
Why a daily pill could change the GLP-1 market — and why convenience still does not answer efficacy, safety, access, and maintenance questions.
Amycretin, CagriSema, and the amylin moment.
The next metabolic medicine story may be less about one receptor and more about multi-pathway satiety signals.
The maintenance plan after GLP-1 weight loss.
Plateaus, protein, resistance training, coverage loss, dose changes, and the question everyone postpones: what happens if you stop?
The MASH-obesity crossover: mazdutide, pemvidutide, survodutide.
Why metabolic therapy is spilling into liver disease headlines, and how to avoid mixing up weight-loss, liver-fat, and MASH endpoints.
Tirzepatide, after the hype.
The uncomfortable parts of the GLP-1 boom that rarely make it into glossy before-and-afters: tolerance, muscle retention, cost, access, and what happens when treatment stops.
Semaglutide vs. Tirzepatide: a 36-week head-to-head.
Mean BMI loss, lean-mass preservation, lipid panels and the side-effect curve nobody charts honestly.
Epitalon: the longevity peptide that won't quit the headlines.
Old research, modern protocols, and why telomere language can sound more settled than the evidence actually is.
Polynucleotide salmon DNA injectables, audited.
What early dermatology data and patient photos suggest: texture looks more plausible than lift, and the word “regenerative” needs a haircut.
The case for early HRT — and the studies that quietly buried the WHI.
Timing, symptom burden, bone density, risk stratification, and why menopause medicine still argues with a 2002 headline.
CJC-1295 / Ipamorelin: the growth-hormone stack, demystified.
Recovery claims, sleep anecdotes, glucose tradeoffs, and why the protocol matters more than the peptide-shop sales page.
Tretinoin at 0.025%, every other night, for ten years.
The boring skincare active that still beats most launches — if your barrier survives the onboarding period.
The Glow Index
Q2 2026 standings · By Glow Verdict score